Suratsawadee Piyaviriyakul

Suratsawadee Piyaviriyakul

Auto-generated profile, based on publicly available information

Suratsawadee Piyaviriyakul

National Cancer Institute, Bangkok 10400

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2023 in Journal of Pharmacy & Pharmacognosy Research
Verified
Journal Article
Open access
JYJantana Yahuafai
Jantana Yahuafai
POPrayumat Onsrisawat
Prayumat Onsrisawat
SPSuratsawadee Piyaviriyakul
Suratsawadee Piyaviriyakul
JNJannarin Nontakham
Jannarin Nontakham
NSNaowarat Suthamnatpong
Naowarat Suthamnatpong
Context: Triphala is a traditional herbal formulation consisting of dried fruits from three plants namely, Terminalia bellirica, Terminalia chebula and Phyllanthus emblica. Its traditional used to treat many ailments, including various types of cancers, health promotion, and longevity. Aims: To evaluate the ability of an aqueous extract Triphala (TPL) to inhibit the growth of Hepatocellular carcinoma cells (HepG2) and in mice. Methods: The anticancer activity of TPL and its composite extracts was assessed in vitro by MTT assay with HepG2 cells. The mice were inoculated with HepG2 cells and then divided randomly into six groups (6 mice/group): control group, positive control group (intraperitoneal with 3 mg/kg body weight doxorubicin), and TPL treatment groups (oral administrated with 50, 100, and 200 mg/kg body weight TPL, respectively). Anticancer activity based on body weight, tumor growth volumes, survival time, relative organ weight, and hematological parameters was determined after administrating the TPL for 14 consecutive days. Results: The results demonstrated that the TPL extract exhibited antiproliferative activity against HepG2 cells in a time-dependent manner of treatment. The selectivity index (SI) showed that TPL is highly selective (SI>3) against the HepG2 cell line and has no activity against non-tumor cells. Oral administration with TPL extract at the dose of 200 mg/kg body weight inhibited tumor growth volume and increase the survival time. No abnormality of hematological parameters, relative organ weight, body weight, and morphology of organs were observed. Conclusions: The TPL extract at the test doses was a non-toxic drug. Our finding reveals the anticancer efficacy of TPL extract.

1 September 2025 in Journal of Human, Earth, and Future
Verified
Journal Article
Open access
PDF file
BWBoonsong Wungsintaweekul
Boonsong Wungsintaweekul
SPS. Piyaviriyakul
S. Piyaviriyakul
JNJ. Nontakham
J. Nontakham
KKK. Kartini
K. Kartini
Twenty-three samples of mangrove plants were refluxed with methanol, then their activities were evaluated. Surprisingly, sample 6 (%SC50 = 5.00 ± 0.08 μg/mL) had the best antioxidation activity among candidates and L-ascorbic acid. Sample 19 was the second, with %SC50 = 5.15 ± 0.15 μg/mL. Both presented the availability of flavonoids and tannins, which was confirmed by phytochemical screening. The antimicrobial assay was done parallelly with the DPPH-free radical scavenging assay. Sample 19 exhibited the highest bacteriostatic activities against S. aureus, A. baumannii, P. aeruginosa (MIC = 62.50 μg/mL), and E. faecalis (MIC = 500 μg/mL) due to the presence of terpenes. In the MTT assay, it was found that sample 19 displayed specific toxicity against KB (%IC50 = 18.51 ± 5.49 μg/mL) and HeLa (%IC50 = 160.68 ± 39.36 μg/mL). Samples 2, 4, and 20 also demonstrated selective toxicity against cancer cells. This is the first report of sample 19, which is the most effective and potent cytotoxic agent against KB, and sample 4, which is the specific and most potent cytotoxic agent against HeLa. This is the first time mangrove plants have been evaluated for their potential to be alternative natural sources of medicine.